N/A
Completed N=75,771
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Source: ClinicalTrials.gov NCT04969419 ↗Enrolled (actual)
75,771
Serious AEs
—
Results posted
Jan 2025
Primary outcomePrimary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
Summary
This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo |
133; 812 | — |
| PRIMARY Number of New Onset Skin Cancers in the Female Sex Subgroup |
78; 429 | — |
| PRIMARY Number of New Onset Skin Cancers in the Male Sex Subgroup |
55; 383 | — |
| PRIMARY Number of New Onset Skin Cancers in the <45 Age Subgroup |
11; 72 | — |
| PRIMARY Number of New Onset Skin Cancers in the 45-64 Age Subgroup |
42; 315 | — |
| PRIMARY Number of New Onset Skin Cancers in the >=65 Age Subgroup |
80; 425 | — |
| PRIMARY Number of New Onset Skin Cancers in the White Ethnicity Subgroup |
103; 563 | — |
| PRIMARY Number of New Onset Skin Cancers in the Non-white Ethnicity Subgroup |
9; 66 | — |
| PRIMARY Number of New Onset Skin Cancers in the Most Deprived Subgroup |
46; 345 | — |
| PRIMARY Number of New Onset Skin Cancers in the Least Deprived Subgroup |
66; 355 | — |
| SECONDARY Prevalence of Skin Cancer in Adult People Diagnosed With Vitiligo |
66; 293 | — |
| SECONDARY Prevalence of Melanoma Skin Cancer in Adult People Diagnosed With Vitiligo |
85; 27 | — |
| SECONDARY Prevalence of Squamous Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo |
13; 72 | — |
| SECONDARY Prevalence of Basal Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo |
31; 161 | — |
| SECONDARY Number of New Onset Actinic Keratoses in Adult People Diagnosed With Vitiligo |
264; 1108 | — |
| SECONDARY Prevalence of Actinic Keratoses in Adult People Diagnosed With Vitiligo |
111; 363 | — |
Eligibility Criteria
Inclusion Criteria
- All eligible adult patients (aged ≥ 18) registered with General Practioner (GP) practices contributing data to OPCRD between January 1, 2010 and December 31, 2020, were eligible for inclusion in the study. People diagnosed with vitiligo prior to the study period (prevalent vitiligo) and people newly diagnosed with vitiligo during the study period (incident vitiligo) are included as cases.
Exclusion Criteria
- People actively registered with the GP practice at that date without a history of vitiligo require a minimum one-year registration with their GP practice.
Data sourced from ClinicalTrials.gov (NCT04969419). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.